Bicara Therapeutics (NASDAQ:BCAX) Shares Gap Down – Here’s What Happened

Bicara Therapeutics Inc. (NASDAQ:BCAX)’s stock price gapped down prior to trading on Tuesday . The stock had previously closed at $27.73, but opened at $22.80. Bicara Therapeutics shares last traded at $24.9350, with a volume of 316,476 shares changing hands.

Key Bicara Therapeutics News

Here are the key news stories impacting Bicara Therapeutics this week:

• Positive Sentiment: Bicara reported second-quarter adjusted earnings of -$0.82 per share, in line with expectations, while investors focused on continued progress in its pivotal cancer trial. Enrollment remains on track for 2026, an important milestone for the company’s lead program. Bicara Therapeutics stock gains as pivotal trial enrollment advances
• Positive Sentiment: Analyst sentiment improved after the results. BTIG Research raised its price target from $28 to $39 and maintained a Buy rating, implying substantial potential upside based on the company’s clinical outlook. Other analysts also increased their forecasts after the quarterly report. Bicara Therapeutics analysts raise forecasts
• Positive Sentiment: Wedbush said the company’s cancer study remains on track for 2026 enrollment, reinforcing expectations that Bicara could reach significant clinical catalysts over the coming months. Bicara Therapeutics cancer study remains on track
• Neutral Sentiment: Analyst views remain mixed. Wells Fargo raised its target from $16 to $23 but retained an Equal Weight rating, placing its target below the stock’s recent trading level. Bicara also announced strategic leadership transitions as it moves into its next phase of execution. Wells Fargo price-target update
• Negative Sentiment: CEO Claire Mazumdar, COO Ryan Cohlhepp and CFO Ivan Hyep collectively sold 41,250 shares for approximately $1.15 million. The transactions were conducted under pre-arranged Rule 10b5-1 plans, and each executive retained a sizable position, reducing—but not eliminating—the negative signal from insider selling. Bicara insider transaction filings

Analysts Set New Price Targets

BCAX has been the topic of several analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Bicara Therapeutics in a report on Monday, July 6th. Wells Fargo & Company raised their price target on shares of Bicara Therapeutics from $16.00 to $23.00 and gave the stock an “equal weight” rating in a research report on Wednesday. Wall Street Zen upgraded shares of Bicara Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday, May 24th. The Goldman Sachs Group upped their price target on shares of Bicara Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a report on Wednesday. Finally, Morgan Stanley increased their price objective on shares of Bicara Therapeutics from $37.00 to $39.00 and gave the company an “overweight” rating in a research note on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $32.73.

Bicara Therapeutics Stock Up 3.7%

The company has a 50 day simple moving average of $26.00 and a 200-day simple moving average of $21.74. The stock has a market cap of $1.62 billion, a price-to-earnings ratio of -7.95 and a beta of -0.75.

Bicara Therapeutics (NASDAQ:BCAX) last issued its earnings results on Tuesday, August 11th. The company reported ($0.82) EPS for the quarter, hitting the consensus estimate of ($0.82). On average, equities research analysts expect that Bicara Therapeutics Inc. will post -3.42 EPS for the current fiscal year.

Insiders Place Their Bets

In other Bicara Therapeutics news, CEO Claire Mazumdar sold 10,000 shares of the business’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $27.98, for a total transaction of $279,800.00. Following the completion of the sale, the chief executive officer owned 362,152 shares in the company, valued at $10,133,012.96. The trade was a 2.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Ivan Hyep sold 28,000 shares of the business’s stock in a transaction on Wednesday, July 8th. The shares were sold at an average price of $28.85, for a total transaction of $807,800.00. Following the sale, the chief financial officer owned 129,855 shares of the company’s stock, valued at approximately $3,746,316.75. The trade was a 17.74% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 129,700 shares of company stock valued at $3,520,725 over the last 90 days. 13.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. bought a new stake in Bicara Therapeutics in the fourth quarter valued at $45,000. Legal & General Group Plc grew its position in shares of Bicara Therapeutics by 64.1% during the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after acquiring an additional 1,233 shares during the last quarter. Larson Financial Group LLC increased its holdings in shares of Bicara Therapeutics by 1,015.5% in the 3rd quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock worth $62,000 after acquiring an additional 3,595 shares during the period. Tower Research Capital LLC TRC increased its holdings in shares of Bicara Therapeutics by 419.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock worth $44,000 after acquiring an additional 3,866 shares during the period. Finally, Caitong International Asset Management Co. Ltd increased its holdings in shares of Bicara Therapeutics by 385.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company’s stock worth $97,000 after acquiring an additional 4,585 shares during the period.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.